Related Experiment Video

Updated: May 14, 2026

The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

Supporting the failing myocardium: is intra-aortic balloon pump enough? The IABP-SHOCK II trial

Smita I Negi1, Biswajit Kar, Igor Gregoric

  • 1Center for Advanced Heart Failure and Heart Transplantation, University of Texas Health Science Center, Houston, TX, USA.

Expert Review of Cardiovascular Therapy
|February 15, 2013
PubMed

Insights

Cardiogenic shock (CS) complicating acute myocardial infarction (AMI) has high mortality. A recent trial found intra-aortic balloon pumps do not improve 30-day outcomes for CS in AMI, challenging current management strategies.

Area of Science:

  • Cardiology
  • Critical Care Medicine
  • Interventional Cardiology

Background:

  • Cardiogenic shock (CS) in acute myocardial infarction (AMI) remains a significant cause of mortality.
  • Intra-aortic balloon pumps (IABP) have been a standard treatment for CS complicating AMI.
  • Recent evidence questions the efficacy of IABP in improving patient outcomes.

Discussion:

  • This review critically examines the findings of Thiele et al.'s randomized controlled trial on IABP use in CS complicating AMI.
  • The trial demonstrated no significant improvement in 30-day mortality or other key outcomes with IABP use.
  • The results necessitate a re-evaluation of current clinical guidelines and treatment protocols.

Key Insights:

  • The use of intra-aortic balloon pumps in cardiogenic shock complicating acute myocardial infarction does not improve 30-day outcomes.
  • This finding challenges the long-standing role of IABP as a primary intervention in this critical condition.
  • Clinical decision-making for CS in AMI must adapt to this new evidence.

Outlook:

  • Future research should focus on alternative or adjunctive therapies for CS in AMI.
  • Exploring novel mechanical circulatory support devices is crucial.
  • Revised clinical practice guidelines are anticipated based on these trial results.

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...